Dexcom

Quality 0.50 · 2 views · Updated 2 months ago

American healthcare company

title: "Dexcom" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["american-companies-established-in-1999", "health-care-companies-established-in-1999", "health-care-companies-based-in-california", "medical-technology-companies-of-the-united-states", "manufacturing-companies-based-in-san-diego", "medical-device-manufacturers", "2005-initial-public-offerings", "1999-establishments-in-california"] description: "American healthcare company" topic_path: "geography/united-states" source: "https://en.wikipedia.org/wiki/Dexcom" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary American healthcare company ::

::data[format=table title="Infobox company"]

FieldValue
nameDexcom, Inc.
image_captionDexcom's headquarters.
typePublic
traded_as
hq_location_citySan Diego, California
hq_location_countryUnited States
key_peopleJacob (Jake) Leach (chairman, president & CEO)
productsMedical devices
foundation
revenue(2024)
operating_income(2024)
net_income(2024)
assets(2024)
equity(2024)
num_employees10,300 (2024)
website
logoDexcom logo.svgclass=skin-invert-image
imageDexcom HQ.jpg
footnotes
::

| name = Dexcom, Inc. | image_caption = Dexcom's headquarters. | type = Public | traded_as = | hq_location_city = San Diego, California | hq_location_country = United States | key_people = Jacob (Jake) Leach (chairman, president & CEO) | products = Medical devices | foundation = | revenue = (2024) | operating_income = (2024) | net_income = (2024) | assets = (2024) | equity = (2024) | num_employees = 10,300 (2024) | website = | logo = Dexcom logo.svgclass=skin-invert-image | image = Dexcom HQ.jpg | footnotes =

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

History

Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second-generation product, the Seven Continuous Glucose Monitoring System, in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment.

During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring system, from the FDA. This product received a CE mark in November 2009. In 2013, development work for integration with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its forthcoming G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. The G5 was approved in 2016 by the FDA for use as a standalone device, while the G6 gained approval in 2018.

Dexcom's first G-series CGM, the G4 Platinum, received a CE mark and FDA approval in 2012 for adults ages 18 and over. This device improved hypoglycemic accuracy by 30%. It also offered a longer range of transmission between the sensor and receiver, as well as a color LCD. The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014. Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps.

The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, the G5 has Bluetooth integrated into its transmitter, enabling it to send data to a mobile device. This allows for use of the device without the standalone receiver. The Dexcom G5 received a CE mark in September 2015.

Dexcom went public in 2005 and is listed on the Nasdaq Global Select Market stock exchange under the ticker symbol DXCM. On April 20, 2020, Dexcom became a component of the Nasdaq-100, replacing American Airlines Group in the index.

The Dexcom G7 was approved in December 2022 by the FDA for use as a standalone device and is the most accurate currently approved CGM in the U.S.

Awards and recognition

In October 2024, Time Magazine named Dexcom Stelo's over-the-counter glucose monitor one of the year's best inventions.

Partnerships

  • Dexcom entered into a partnership in 2015 with Google Life Sciences (which subsequently became Verily) to develop the Dexcom G7
  • Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem's t:slim X2 insulin pump and the Dexcom G6 "to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes."
  • In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen into both companies' software applications.
  • Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo's platform. This integration allowed Livongo to incorporate the CGM data along with other patient data.
  • In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet's tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery. This allowed the ability to adjust insulin doses based on Insulet's algorithm or through their smartphone.
  • The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for diabetes management.
  • In November 2024, Dexcom announced a "strategic partnership" and data exchange with Oura.

Venture capital arm

In early 2021, Dexcom launched Dexcom Ventures, a venture capital arm focused on emerging continuous glucose monitoring technologies and devices measuring the levels of other types of substances and analytes. In practice, Dexcom Ventures has also invested in cybersecurity platforms for the software used in medical devices.

References

References

  1. (February 18, 2025). "2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission.
  2. (26 April 2022). "Dexcom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People with Diabetes".
  3. "Dexcom adding 500 jobs in Mesa".
  4. (August 7, 2013). "Freedom Meditech raises $7 million".
  5. (January 7, 2008). "Insulet Corporation and DexCom Announce Development Agreement (NASDAQ:DXCM)". Investor.shareholder.com.
  6. (June 10, 2008). "DexCom™ Announces Joint Development Agreement with Animas Corporation". Investor.shareholder.com.
  7. (November 10, 2008). "Edwards Lifesciences and DexCom to Develop Continuous Glucose Monitoring Products for Hospital Market (NASDAQ:DXCM)". Investor.shareholder.com.
  8. (July 30, 2015). "Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems". PR Newswire.
  9. (March 27, 2018). "FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices". FDA.
  10. (11 October 2012). "FDA Nod for Dexcom G4 Platinum - Analyst Blog". Zacks.
  11. (13 June 2018). "DexCom Stock History".
  12. (19 February 2014). "FDA Approves Pediatric Use for Dexcom's G4 Platinum CGM".
  13. (January 29, 2015). "Dexcom G4 Platinum With SHARE Gets FDA Approval".
  14. (25 August 2015). "Dexcom wins FDA nod for G5 CGM".
  15. (25 August 2015). "FDA approves Dexcom for Bluetooth-enabled CGM G5".
  16. (14 September 2015). "Dexcom gets CE Mark for G5 continuous glucose monitor".
  17. (April 10, 2020). "Dexcom, inc. to join the NASDAQ-100 Index beginning April 20, 2020". [[Nasdaq]].
  18. (8 December 2022). "Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.".
  19. Klein, Jessica. (2024-10-30). "Dexcom Stelo: the 200 Best Inventions of 2024".
  20. "Fierce Biotech".
  21. "Verily Life Sciences".
  22. "Dexcom G7 CGM - Powerfully simple diabetes management".
  23. (7 August 2015). "FDA Approval of Tandem's t:slim with Integrated Dexcom G4 Platinum CGM Expected in 2015".
  24. "FDA Approves New Insulin Pump-Continuous Sensor Combo".
  25. (13 December 2019). "FDA approves new closed-loop insulin delivery system for people with Type 1 diabetes".
  26. (June 7, 2019). "DexCom and Companion Medical Collaboration to Support CGM".
  27. (14 January 2020). "JPM20: Livongo strikes deal with Dexcom to integrate continuous glucose monitoring data".
  28. (February 24, 2020). "Insulet Partners With Dexcom for Automated Insulin Delivery".
  29. (20 February 2020). "Insulet's Omnipod to integrate with Dexcom, Abbott CGMS for automated, smartphone-controlled dosing".
  30. (12 March 2020). "Dexcom G6 integration enables insights from Welldoc BlueStar, Apple's rumored video workout app and more digital health news briefs".
  31. "Dexcom and ŌURA Announce Strategic Partnership".
  32. Freeman, Mike. (2021-02-13). "Dexcom unveils new corporate venture fund to invest in sensor, health monitoring startups".
  33. MedCrypt. "MedCrypt Extends Series B with Additional Investment from Dexcom Ventures".

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

american-companies-established-in-1999health-care-companies-established-in-1999health-care-companies-based-in-californiamedical-technology-companies-of-the-united-statesmanufacturing-companies-based-in-san-diegomedical-device-manufacturers2005-initial-public-offerings1999-establishments-in-california